Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPPIK pediatric sparsentan study in proteinuric glomerular diseases
2023-505497-14-00Phase 2Authorised
- Sponsor
- Travere Therapeutics
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of sparsentan in focal segmental glomerulosclerosis (FSGS), nephrosis, IgA nephropathy (IgAN) and 2 more (3 arms), sponsored by Travere Therapeutics. Primary endpoints: Safety and tolerability and Change in urine protein/creatinine ratio. Planned start Jun 2024; status: authorised.
02
Drugs
sparsentan
03
Conditions
focal segmental glomerulosclerosis (FSGS)nephrosisIgA nephropathy (IgAN)Henoch-Schönlein Purpura (HSP)Alport syndrome
Beyond the preview
Go deeper on 2023-505497-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505497-14-00.